Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy

T. van der Kwast, N. Al Daoud, L. Collette, J. Sykes, J. Thoms, M. Milosevic, R. G. Bristow, G. van Tienhoven, P. Warde, R. O. Mirimanoff, M. Bolla

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Aim: We investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in biopsies and transurethral resections prior to external beam radiotherapy with or without androgen deprivation. Methods: Cohort 1 consisted of 118 intermediate risk prostate cancer patients treated by radiotherapy, with biochemical relapse as primary end-point (median follow-up 6.5 years). Cohort 2 consisted of 132 high risk patients, enrolled in a phase III randomised trial (EORTC 22863) comparing radiotherapy alone to radiotherapy with long-term androgen deprivation (LTAD) with clinical progression free survival as primary end-point (median follow-up 9.1 years). Presence of IDC-P was identified after central review. Multivariable regression modelling and Kaplan-Meier analysis were performed with IDC-P as dichotomous variable. Results: IDC-P was a strong prognosticator for early (<36 months) biochemical relapse (HR 7.3; p = 0.007) in cohort 1 and for clinical disease-free survival in both arms of cohort 2 (radiotherapy arm: HR 3.5; p < 0.0001; radiotherapy plus LTAD arm: HR 2.8, p = 0.018). IDC-P retained significance after stratification for reviewed Gleason score in the radiotherapy arm (HR 2.3; p = 0.03). IDC-P was a strong prognosticator for metastatic failure rate (radiotherapy arm: HR 5.3; p < 0.0001; radiotherapy plus LTAD arm: HR 3.6; p = 0.05). Conclusions: IDC-P in diagnostic samples of patients with intermediate or high risk prostate cancer is an independent prognosticator of early biochemical relapse and metastatic failure rate after radiotherapy. We suggest that the presence of IDC-P in prostate biopsies should routinely be reported. © 2011 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)1318-1325
JournalEuropean Journal of Cancer
Volume48
Issue number9
DOIs
Publication statusPublished - 2012
Externally publishedYes

Cite this

van der Kwast, T. ; Al Daoud, N. ; Collette, L. ; Sykes, J. ; Thoms, J. ; Milosevic, M. ; Bristow, R. G. ; van Tienhoven, G. ; Warde, P. ; Mirimanoff, R. O. ; Bolla, M. / Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. In: European Journal of Cancer. 2012 ; Vol. 48, No. 9. pp. 1318-1325.
@article{24299c3b0a944ad5afb55c5470f78057,
title = "Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy",
abstract = "Aim: We investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in biopsies and transurethral resections prior to external beam radiotherapy with or without androgen deprivation. Methods: Cohort 1 consisted of 118 intermediate risk prostate cancer patients treated by radiotherapy, with biochemical relapse as primary end-point (median follow-up 6.5 years). Cohort 2 consisted of 132 high risk patients, enrolled in a phase III randomised trial (EORTC 22863) comparing radiotherapy alone to radiotherapy with long-term androgen deprivation (LTAD) with clinical progression free survival as primary end-point (median follow-up 9.1 years). Presence of IDC-P was identified after central review. Multivariable regression modelling and Kaplan-Meier analysis were performed with IDC-P as dichotomous variable. Results: IDC-P was a strong prognosticator for early (<36 months) biochemical relapse (HR 7.3; p = 0.007) in cohort 1 and for clinical disease-free survival in both arms of cohort 2 (radiotherapy arm: HR 3.5; p < 0.0001; radiotherapy plus LTAD arm: HR 2.8, p = 0.018). IDC-P retained significance after stratification for reviewed Gleason score in the radiotherapy arm (HR 2.3; p = 0.03). IDC-P was a strong prognosticator for metastatic failure rate (radiotherapy arm: HR 5.3; p < 0.0001; radiotherapy plus LTAD arm: HR 3.6; p = 0.05). Conclusions: IDC-P in diagnostic samples of patients with intermediate or high risk prostate cancer is an independent prognosticator of early biochemical relapse and metastatic failure rate after radiotherapy. We suggest that the presence of IDC-P in prostate biopsies should routinely be reported. {\circledC} 2011 Elsevier Ltd. All rights reserved.",
author = "{van der Kwast}, T. and {Al Daoud}, N. and L. Collette and J. Sykes and J. Thoms and M. Milosevic and Bristow, {R. G.} and {van Tienhoven}, G. and P. Warde and Mirimanoff, {R. O.} and M. Bolla",
year = "2012",
doi = "10.1016/j.ejca.2012.02.003",
language = "English",
volume = "48",
pages = "1318--1325",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",
number = "9",

}

van der Kwast, T, Al Daoud, N, Collette, L, Sykes, J, Thoms, J, Milosevic, M, Bristow, RG, van Tienhoven, G, Warde, P, Mirimanoff, RO & Bolla, M 2012, 'Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy' European Journal of Cancer, vol. 48, no. 9, pp. 1318-1325. https://doi.org/10.1016/j.ejca.2012.02.003

Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. / van der Kwast, T.; Al Daoud, N.; Collette, L.; Sykes, J.; Thoms, J.; Milosevic, M.; Bristow, R. G.; van Tienhoven, G.; Warde, P.; Mirimanoff, R. O.; Bolla, M.

In: European Journal of Cancer, Vol. 48, No. 9, 2012, p. 1318-1325.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy

AU - van der Kwast, T.

AU - Al Daoud, N.

AU - Collette, L.

AU - Sykes, J.

AU - Thoms, J.

AU - Milosevic, M.

AU - Bristow, R. G.

AU - van Tienhoven, G.

AU - Warde, P.

AU - Mirimanoff, R. O.

AU - Bolla, M.

PY - 2012

Y1 - 2012

N2 - Aim: We investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in biopsies and transurethral resections prior to external beam radiotherapy with or without androgen deprivation. Methods: Cohort 1 consisted of 118 intermediate risk prostate cancer patients treated by radiotherapy, with biochemical relapse as primary end-point (median follow-up 6.5 years). Cohort 2 consisted of 132 high risk patients, enrolled in a phase III randomised trial (EORTC 22863) comparing radiotherapy alone to radiotherapy with long-term androgen deprivation (LTAD) with clinical progression free survival as primary end-point (median follow-up 9.1 years). Presence of IDC-P was identified after central review. Multivariable regression modelling and Kaplan-Meier analysis were performed with IDC-P as dichotomous variable. Results: IDC-P was a strong prognosticator for early (<36 months) biochemical relapse (HR 7.3; p = 0.007) in cohort 1 and for clinical disease-free survival in both arms of cohort 2 (radiotherapy arm: HR 3.5; p < 0.0001; radiotherapy plus LTAD arm: HR 2.8, p = 0.018). IDC-P retained significance after stratification for reviewed Gleason score in the radiotherapy arm (HR 2.3; p = 0.03). IDC-P was a strong prognosticator for metastatic failure rate (radiotherapy arm: HR 5.3; p < 0.0001; radiotherapy plus LTAD arm: HR 3.6; p = 0.05). Conclusions: IDC-P in diagnostic samples of patients with intermediate or high risk prostate cancer is an independent prognosticator of early biochemical relapse and metastatic failure rate after radiotherapy. We suggest that the presence of IDC-P in prostate biopsies should routinely be reported. © 2011 Elsevier Ltd. All rights reserved.

AB - Aim: We investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in biopsies and transurethral resections prior to external beam radiotherapy with or without androgen deprivation. Methods: Cohort 1 consisted of 118 intermediate risk prostate cancer patients treated by radiotherapy, with biochemical relapse as primary end-point (median follow-up 6.5 years). Cohort 2 consisted of 132 high risk patients, enrolled in a phase III randomised trial (EORTC 22863) comparing radiotherapy alone to radiotherapy with long-term androgen deprivation (LTAD) with clinical progression free survival as primary end-point (median follow-up 9.1 years). Presence of IDC-P was identified after central review. Multivariable regression modelling and Kaplan-Meier analysis were performed with IDC-P as dichotomous variable. Results: IDC-P was a strong prognosticator for early (<36 months) biochemical relapse (HR 7.3; p = 0.007) in cohort 1 and for clinical disease-free survival in both arms of cohort 2 (radiotherapy arm: HR 3.5; p < 0.0001; radiotherapy plus LTAD arm: HR 2.8, p = 0.018). IDC-P retained significance after stratification for reviewed Gleason score in the radiotherapy arm (HR 2.3; p = 0.03). IDC-P was a strong prognosticator for metastatic failure rate (radiotherapy arm: HR 5.3; p < 0.0001; radiotherapy plus LTAD arm: HR 3.6; p = 0.05). Conclusions: IDC-P in diagnostic samples of patients with intermediate or high risk prostate cancer is an independent prognosticator of early biochemical relapse and metastatic failure rate after radiotherapy. We suggest that the presence of IDC-P in prostate biopsies should routinely be reported. © 2011 Elsevier Ltd. All rights reserved.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84861332523&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/22405699

U2 - 10.1016/j.ejca.2012.02.003

DO - 10.1016/j.ejca.2012.02.003

M3 - Article

VL - 48

SP - 1318

EP - 1325

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -